

SANUWAVE Health, Inc.  
Form 8-K  
October 13, 2015  
**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **October 8, 2015**

**SANUWAVE Health, Inc.**  
(Exact name of registrant as specified in its charter)

**Nevada**                                **000-52985**    **20-1176000**  
(State or other jurisdiction (Commission(IRS Employer  
File  
of incorporation)                Number)    Identification No.)

**11475 Great Oaks Way, Suite 150,**    **30022**  
**Alpharetta, Georgia**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code    **(678) 581-6843**

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: SANUWAVE Health, Inc. - Form 8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 7.01 Regulation FD Disclosure**

On October 8, 2015, SANUWAVE Health, Inc., a Nevada Corporation (the "Company"), provided an update on the Company's Phase III supplemental clinical trial that used the dermaPACE<sup>®</sup> for the treatment of diabetic foot ulcers. A copy of the related press release is attached as Exhibit 99.1 to this Form 8-K.

The Company hosted a conference call with investors on October 8, 2015 at 9 a.m., Eastern Time, to discuss the dermaPACE clinical trial. A copy of management's prepared remarks is attached hereto as Exhibit 99.2.

The information in this Item 7.01 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release, dated October 8, 2015, issued by SANUWAVE Health, Inc., titled "SANUWAVE Health releases dermaPACE clinical trial top line data and preliminary data analysis results."
99.2	Management's prepared remarks for the October 8, 2015, SANUWAVE Health, Inc. conference call to discuss the dermaPACE clinical trial.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SANUWAVE HEALTH, INC.

Dated: October 13, 2015

By: */s/ Lisa E. Sundstrom*  
Name: Lisa E. Sundstrom  
Title: Controller and interim Chief  
Financial Officer

---

**EXHIBIT INDEX**

<b><u>Exhibit</u> <u>No.</u></b>	<b>Description</b>
99.1	Press release, dated October 8, 2015, issued by SANUWAVE Health, Inc., titled “SANUWAVE Health releases dermaPACE clinical trial top line data and preliminary data analysis results.”
99.2	Management’s prepared remarks for the October 8, 2015, SANUWAVE Health, Inc. conference call to discuss the dermaPACE clinical trial.